Sprouty proteins, masterminds of receptor tyrosine kinase signaling
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 1×
“Another conserved RTK pathway that can be activated is that mediated by PLCc, which converts phosphatidylinositol [4, 5]-bisphosphate (PIP2) into two second messengers: inositol [1, 4, 5] trisphosphate (IP3) and diacylglycerol (DAG), leading to calcium (Ca) mobilization.”
BackgroundAngiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · cited 1×
“mal growth factor (EGF), ephrins, and angiopoietins (Angs), in conjunction with their cognate receptors play a crucial role in blood vessel formation in normal and pathological settings (reviewed in [8, 9]).”
BackgroundThe discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227 · cited 2×
“Receptor tyrosine kinases (RTKs) have been at the forefront of cancer research for many years due to their pivotal role in cancer biology as prognostic indicators and therapeutic targets [1, 2].”
BackgroundEndothelial cells and VEGF in vascular development
Coultas, L., Chawengsaksophak, K., & Rossant, J. (2005) · Nature · doi:10.1038/nature04479 · Cited by 1,016 · cited 1×
“VEGF-induced signal transduction is the most critical and best studied signaling pathway in endothelial cells and plays a central role in vascular development and in physiological and pathological angiogenesis [65].”
BackgroundSprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway
Hanafusa, H., Torii, S., Yasunaga, T., & Nishida, E. (2002) · Nature Cell Biology · doi:10.1038/ncb867 · Cited by 566 · cited 3×
“Mutation of this tyrosine generates a dominant-negative Spry unable to inhibit FGFstimulated MAPK activation [24, 48, 49].”
BackgroundSprouty, an intracellular inhibitor of Ras signaling
Casci, T., Vinós, J., & Freeman, M. (1999) · Cell · doi:10.1016/s0092-8674(00)80576-0 · Cited by 467 · cited 1×
“Initially, both Spry1 and Spry2 have been proposed to bind Grb2 via the N-terminal conserved tyrosine residue, thus interrupting the signaling cascade before MAPK can be activated [22, 43, 45, 49, 54] (Fig.”
BackgroundWingrove, J. A., & O'Farrell, P. H. (1999) · Cell · doi:10.1016/s0092-8674(00)80610-8 · Cited by 249 · cited 1×
“Curiously, ectopic expression of nitric oxide synthase (NOS) in Drosophila mimics the dSpry mutation of increased tracheal branching [87].”
Background
Cited by
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Wound Healing: A Cellular Perspective
Rodrigues, M., Kosaric, N., Bonham, C. A., & Gurtner, G. C. (2019) · Physiological Reviews · doi:10.1152/physrev.00067.2017 · Cited by 3,013
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
“FGF signalling activates sprouty proteins, which can then in turn inhibit FGF stimulation of the MAPK pathway by interacting with GRB2 (growth factor receptor bound protein 2), SOS1 or RAF1 (Ref”
Fibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 534
Raf Family Kinases: Old Dogs Have Learned New Tricks
Matallanas, D., Birtwistle, M., Romano, D., Zebisch, A., Rauch, J., von Kriegsheim, A., & Kolch, W. (2011) · Genes & Cancer · doi:10.1177/1947601911407323 · Cited by 386
Metadata
- Authors
- Cabrita, M. A., & Christofori, G.
- Venue
- Angiogenesis
- Published
- 2008-01-25
- Volume
- 11
- Issue
- 1
- Pages
- 53-62
- ISSN
- 0969-6970 (ISSN-L)
- 1573-7209
- OpenAlex
- W2115607198
- Cited by
- 229
- References
- 9
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.